Project Grant R21AR086402
Award Date 8/11/26
Completion Date 7/31/28
Dollars Obligated $341K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Florida $1.768 million on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to assess magnetic resonance measures of bioenergetics and microvascular function in Duchenne and Becker muscular dystrophy. The project evaluates whether MR-based measures of muscle energetics and blood vessel function can track disease progression and treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $421,367 to the University of Arkansas for Medical Sciences on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate microvascular integrity and its role in osteoarthritis development. The project examines how damage to blood vessels within the joint contributes to osteoarthritis pathology, specifically testing whether mechanical stress–induced...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $607,599 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a hybrid biomaterial immunotherapy system for rheumatoid arthritis. The funded work centers on engineering and testing REGVAK, a novel hybrid polymeric microparticle–lipid nanoparticle system designed to address the root cause of rheumatoid arthritis by targeting dendritic cell activation...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Northeastern University $652,195 on June 17, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and test surface-modified, cartilage-targeting exosomes as non-viral gene delivery vehicles for osteoarthritis treatment. The project engineers charge-reversed cationic exosomes derived from mesenchymal stem cells, anchored with arginine-rich peptide motifs, to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Syracuse University $467,076 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop multifunctional microcarriers for immune modulation in osteoarthritis treatment. The project addresses post-traumatic osteoarthritis (PTOA) by investigating site-specific delivery of a macrophage-targeting agent via calcium-zoledronate nanoparticle-loaded microparticles...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Ventura Life Sciences, LLC $305,443 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop novel AAV capsids for skeletal muscle gene therapy. The recipient will employ directed evolution methods, high-throughput screening, and immune assays to engineer and validate adeno-associated virus (AAV) capsid variants with improved transduction capability...
- The University of Florida, through its Division of Sponsored Research, received a $1.83 million Project Grant award dated September 5, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports a three-year research project through August 31, 2028, investigating the role of NADPH oxidases (NOX) in sepsis-induced myopathy and impaired muscle regeneration. The...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of Colorado $348,339 on May 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research on the mechanical role of hyaluronic acid in tendon fibers and how glycosaminoglycan depletion affects strain recovery in collagen. The research employs laser ablation of collagen fibers within intact tendons and enzymatic treatments...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Connecticut Health Center $658,289 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a minimally invasive periarticular injection therapy for managing knee osteoarthritis pain. The project will engineer a combination treatment comprising local anesthetics and a pain modulator delivered via periarticular injection—rather than...